Charoenkwan Pimlak, Traisrisilp Kuntharee, Sirichotiyakul Supatra, Phusua Arunee, Sanguansermsri Torpong, Tongsong Theera
Department of Pediatrics, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand.
Thalassemia and Hematology Center, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand.
Fetal Diagn Ther. 2022;49(11-12):468-478. doi: 10.1159/000528033. Epub 2022 Dec 27.
Prenatal diagnosis of thalassemia disease was usually based on invasive technique. Noninvasive diagnosis using cell-free fetal DNA (cff-DNA) was described with various laboratory techniques. The aim of this study was to identify the performance of dPCR for analyzing cff-DNA in maternal plasma to diagnose fetal beta-thalassemia diseases.
Thirty-five couples at risk of fetal beta-thalassemia disease caused by four common mutations of HBB were enrolled at 12-18 weeks. The dPCR assay was designed to detect and quantify paternally inherited beta-thalassemia allele (PIB) and maternally inherited beta-thalassemia allele (MIB) from cff-DNA in maternal plasma.
Of 29 couples with different paternal/maternal mutations, all cases who inherited paternal mutation had detectable PIB-M. The MIB-mutant/wild-type (MIB-M/MIB-N) ratio in the mothers whose fetuses did not inherit maternal mutation was 0.87 ± 0.07 which was significantly lower than that of the mothers whose fetuses inherited maternal mutation, 1.01 ± 0.05. The sensitivity and specificity of MIB-M/MIB-N ratio >0.95 in predicting fetus inheriting maternal mutation were 100 and 92.3%, respectively. In four couples with same paternal/maternal mutation, IB-M/IB-N ratio of >0.95 correctly predicted the presence of an inheritance of at least one beta-thalassemia allele. In two couples with paternal Hb E/beta-thalassemia, the presence of PIB-M and the MIB-M/MIB-N ratio of >0.95 correctly predicted the presence of paternal/maternal mutations, respectively.
The method of analyzing cff-DNA in maternal plasma by dPCR is efficient for prenatal diagnosis of beta-thalassemia.
地中海贫血疾病的产前诊断通常基于侵入性技术。使用游离胎儿DNA(cff-DNA)的非侵入性诊断已通过各种实验室技术进行了描述。本研究的目的是确定数字PCR(dPCR)分析母血中cff-DNA以诊断胎儿β地中海贫血疾病的性能。
招募了35对因HBB的四种常见突变而有胎儿β地中海贫血疾病风险的夫妇,孕周为12至18周。设计dPCR检测法以从母血中的cff-DNA检测和定量父系遗传的β地中海贫血等位基因(PIB)和母系遗传的β地中海贫血等位基因(MIB)。
在29对具有不同父系/母系突变的夫妇中,所有继承父系突变的病例均可检测到PIB-M。胎儿未继承母系突变的母亲中,MIB-突变型/野生型(MIB-M/MIB-N)比值为0.87±0.07,显著低于胎儿继承母系突变的母亲,后者为1.01±0.05。MIB-M/MIB-N比值>0.95预测胎儿继承母系突变的敏感性和特异性分别为100%和92.3%。在4对具有相同父系/母系突变的夫妇中,IB-M/IB-N比值>0.95正确预测了至少一个β地中海贫血等位基因的遗传情况。在2对父系为Hb E/β地中海贫血的夫妇中,PIB-M的存在以及MIB-M/MIB-N比值>0.95分别正确预测了父系/母系突变的存在。
通过dPCR分析母血中cff-DNA的方法对β地中海贫血的产前诊断有效。